Stocktoria
Clearside Biomedical, Inc. CLSDQ
Clearside Biomedical, Inc. (CLSDQ) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2024 revenue was $1.7M at a -2064.4% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
Beneish M-score: -1.34 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 1906 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CLSDQ | Clearside Biomedical, Inc. | 2/9 | — | — | — |
| RANI | Rani Therapeutics Holdings, Inc. | 4/9 | -4.67 | — | — |
| SXTC | China SXT Pharmaceuticals, Inc. | 3/9 | 2.19 | — | — |
| NRXP | NRX Pharmaceuticals, Inc. | 4/9 | — | — | — |
| BIOE | Bio Essence Corp | 9/9 | — | 14.1 | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | 4/9 | — | — | — |
| LPCN | Lipocine Inc. | — | — | — | -82.3% |
FAQ
Is CLSDQ financially healthy?
Clearside Biomedical, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does CLSDQ pay a dividend?
No, Clearside Biomedical, Inc. does not currently pay a dividend.
How profitable is CLSDQ?
In FY2024, Clearside Biomedical, Inc. had a net margin of -2064.4%.
Source: SEC EDGAR filings · CIK 0001539029 · US · as of 2024-12-31. facts plus Stocktoria's own computed scores — not investment advice.